Cell Constructs is a regenerative healthcare company dedicated to improving wound care healing, leveraging proprietary medical device technologies and biotechnology research and development. There are approximately 350 million people worldwide with diabetes, with up to 90 million people affected in the U.S. and Europe alone. Of these, it’s estimated that 14 million people suffer from chronic wounds annually. Complications from chronic wounds can lead to debilitating and life-threatening complications as well as increased healthcare costs.1 The Company’s first device, ProgenaMatrix™, is an active wound care solution utilizing human keratin. The company was founded in 2008 by experienced scientists from biotechnology and medical device disciplines and is headquartered in Marietta, Georgia, U.S.A.
1. Armstrong DG, Boulton AJM, Bus SA. Diabetic foot ulcers and their recurrence. N Engl J Med 2017;376:2367-7.
ProgenaMatrix is currently undergoing a 510k premarket review by FDA for dry, light and moderately exuding partial and full thickness wounds. Not available for sale or other clinical use.